Changing trends in the management of chronic granulocytic-leukemia.
Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.